Shots:
- Daiichi Sankyo has dosed the first patient in the P-III (TROPIONLung17) trial of Datroway for TROP2-NMR–positive LA/M nonsq. NSCLC without actionable genomic alterations previously treated with immunotherapy (IT) & Pt-based CT
- Trial will evaluate Datroway (6mg/kg) vs docetaxel in above-mentioned pts (n=~400) across Asia, EU & North America, assessing PFS & OS as dual 1EPs & key 2EPs incl. ORR, DoR & safety
- Datroway is being evaluated in 4 P-III (AVANZAR, TROPION-Lung07, 08 & 10) trials with IT for tumors without actionable genomic alterations, in a P-III (TROPION-Lung14) trial with osimertinib for EGFRm NSCLC, & in a later-line P-III (TROPION-Lung15) study assessing Datroway ± Osimertinib
Ref: Daiichi Sankyo | Image: Daiichi Sankyo | Press Release
Related News: Daiichi Sankyo Reports First Patient Dosing in P-III (DESTINY-Endometrial02) Trial of Enhertu for HER2+ Endometrial Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
